MarketBeat
03 Oct 2026, 07:03 UTC · 13h ago
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Impact · against what's priced in
Amylyx's positive Phase III trial for avexitide significantly derisks its PBH pipeline, providing a clear path to an FDA filing by year-end. The high statistical significance of the primary endpoint and the identification of a substantial U.S. addressable market (120k-160k patients) create a material catalyst for future growth and commercial launch in 2027.
- AMLX+0.90
No priced-in read yet
- In context
The Phase III trial met its primary endpoint with a high level of statistical significance (p=0.000003), reducing Level 2 and 3 hypoglycemic events by 55%, which supports an NDA filing before the end of 2026.
Read from the article alone
